Prevention of myopia shift and myopia onset using 0.01% atropine in premyopic children — a prospective, randomized, double-masked, and crossover trial

Conclusion: Within the limits of only two consecutive 6-month observation period, 0.01% atropine eye drops effectively prevented myopic shift, axial elongation, and myopia onset in premyopic children.Trial registration: This trial was registered in the Chinese Clinical Trial Registry (Registration number: ChiCTR2000034760). Registered 18 July 2020.What is Known:• Minimal studies on interventions for pre-myopia, despite the International Myopia Institute stating that preventing myopia is an “even more valuable target” for science and practice than reducing progression after onset.What is New:• A total of 0.01% atropine eye drops may safely and effectively reduce the proportion of myopia onset and fast myopic shift in premyopic schoolchildren.
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research